Completed PHASE2 INTERVENTIONAL 5-arm NCT00809159

Double Blind, Placebo Controlled Study to Assess Efficacy of AIN457 in Moderate to Severe Ankylosing Spondylitis

Randomized, Placebo Controlled Double Blind, Multi-center Phase II Proof-of-concept Study to Assess the Efficacy of AIN457 in Patients With Moderate to Severe Ankylosing Spondylitis

Sponsor: Novartis Pharmaceuticals

Conditions Ankylosing Spondylitis

Interventions AIN457 Placebo

Updated 7 times since 2017 Last updated: Dec 7, 2015 Started: Mar 31, 2009 Primary completion: May 31, 2011 Completion: May 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00809159, this PHASE2 trial focuses on Ankylosing Spondylitis and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 7 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Benbrook, United States , Berlin, Germany , Duncansville, United States , Hamburg, Germany , Herne, Germany , Jackson, United States , Knoxville, United States , Leeds, United Kingdom , Maastricht, Netherlands and 9 more locations